SCHEMBL979232

SCHEMBL979232

FC(F)(F)c1ccc2ncsc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
MEN1 O00255 1/20 0.57
POLB P06746 1/20 0.57
KMT2A Q03164 1/20 0.57
NTRK1 P04629 3/20 0.51
NTRK2 Q16620 3/20 0.51
EPHX2 P34913 1/20 0.50
SCN4A P35499 1/20 0.50
KDM4E B2RXH2 2/20 0.47
HKDC1 Q2TB90 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALDH1A1 P00352 1/20 0.45
HSD17B10 Q99714 1/20 0.45
DYRK1A Q13627 3/20 0.45
DYRK3 O43781 1/20 0.43
CLK1 P49759 1/20 0.43
CLK2 P49760 1/20 0.43
CLK3 P49761 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18004102 0.86 NPC1 (0.56) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL1538312 0.85 NPC1 (0.47) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL30375905 0.85 NPC1 (0.47) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL18003523 0.82 NPC1 (0.52) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL761993 0.81 MEN1 (0.52) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL25054159 0.78 NPC1 (0.45) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL4432370 0.76 NPC1 (0.59) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL264940 0.75 NPC1 (0.55) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL10235035 0.75 RAB9A (0.42) NPC1RAB9AMEN1POLBKMT2A
SCHEMBL20991103 0.75 NPC1 (0.42) NPC1RAB9AMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
EP-1931659-B1 DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2010-09-08 EP claimed
US-7655679-B2 Derivatives of 2-aminothiazoles and 2-amino-oxazoles, processes for their preparation and their use as pharmaceutical compositions SANOFI-AVENTIS (FR) 2010-02-02 US claimed
CN-101277953-A Atives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals SANOFI AVENTIS (FR) 2008-10-01 CN claimed
US-20080227834-A1 DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS SANOFI-AVENTIS (FR) 2008-09-18 US claimed
EP-1931659-A1 DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP claimed
WO-2007039176-A1 DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO claimed
US-12622896-B2 Antiviral compounds, compositions and methods of use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2026-05-12 US disclosed
WO-2026090589-A1 HETEROCYCLIC HBS1L DEGRADERS TANGO THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
EP-4406957-B1 ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME NOGRA PHARMA LTD (IE) 2026-04-08 EP disclosed
US-12577256-B2 Aryl receptor modulators and methods of making and using the same NOGRA PHARMA LIMITED (IE) 2026-03-17 US disclosed
US-20250129063-A1 BENZOTHIAZOLE COMPOUNDS AS VHL LIGANDS GENENTECH, INC. (US) 2025-04-24 US disclosed
CN-119677735-A Benzothiazole compounds as VHL ligands 基因泰克公司 2025-03-21 CN disclosed
US-20080227834-A1 DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS SANOFI-AVENTIS (FR) 2008-09-18 US disclosed
US-20080207905-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same SAMSUNG ELECTRONICS CO., LTD., (KR) 2008-08-28 US disclosed
EP-1939189-A1 DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY SHIONOGI & CO., LTD. (JP) 2008-07-02 EP disclosed
EP-1931659-A1 DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007078180-A1 METALLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE SAME INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, HANYANG UNIVERSITY (KR) 2007-07-12 WO disclosed
WO-2007039176-A1 DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed
US-4179296-A CONTAINING A BENZIMIDAZOLOCARBOCYANINE DYE AND AT LEAST ONE OTHER CYANINE DYE FUJI PHOTO FILM CO., LTD. (JP) 1979-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577256-B2 Aryl receptor modulators and methods of making and using the same AHR, IL23R, ARNT NPC1 3205/4885RAB9A 4214/4885MEN1 4746/4885
US-20080227834-A1 DERIVATIVES OF 2-AMINOTHIAZOLES AND 2-AMINO-OXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS PPARA, PPARD, PPARG NPC1 3355/4885RAB9A 4608/4885MEN1 4730/4885
US-20250129063-A1 BENZOTHIAZOLE COMPOUNDS AS VHL LIGANDS VHL, BRCA1, GLS NPC1 288/4885RAB9A 2053/4885MEN1 2564/4885
US-20080207905-A1 Metallic Compound and Organic Electroluminescence Device Comprising the Same NOX5, PRMT5, SIRT5 NPC1 4183/4885RAB9A 1882/4885MEN1 470/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR NPC1 917/4885RAB9A 1863/4885MEN1 722/4885
US-12622896-B2 Antiviral compounds, compositions and methods of use SARS1, NSUN2, ZC3HAV1 NPC1 30/4885RAB9A 3269/4885MEN1 3754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.